Hypertrophic Cardiomyopathy Market

Market Overview:

The 7 major hypertrophic cardiomyopathy markets reached a value of US$ 312.5 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 356.7 Million by 2034, exhibiting a growth rate (CAGR) of 1.21% during 2024-2034.

The hypertrophic cardiomyopathy market has been comprehensively analyzed in IMARC's new report titled "Hypertrophic Cardiomyopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hypertrophic cardiomyopathy refers to a condition in which the cardiac muscle becomes abnormally thick. The parts of the heart most frequently affected are the ventricles and the interventricular septum. This can make the heart walls stiff and reduce its ability to pump blood effectively, resulting in electrical conduction problems. Individuals suffering from the disease may experience fatigue, leg swelling, shortness of breath, chest pain, fainting, etc. The other common symptoms of hypertrophic cardiomyopathy include abnormal heart rhythms (arrhythmias), dizziness, lightheadedness, etc. These indications may be worse if a person is dehydrated. The diagnosis of the ailment is typically made using the medical history and underlying symptoms of the patient, along with a physical exam and laboratory tests. The healthcare provider may also perform numerous diagnostic procedures, such as an electrocardiogram, cardiac magnetic resonance imaging, echocardiogram, etc. Additionally, stress tests and genetic testing can be utilized to confirm a diagnosis among patients.

The rising cases of inherited genetic mutations that affect the proteins in heart muscle cells are primarily driving the hypertrophic cardiomyopathy market. In addition to this, the elevating incidences of several associated risk factors, including sedentary lifestyle, obesity, aging, high blood pressure, intense endurance exercise, etc., are further augmenting the market growth. Moreover, the emerging popularity of effective medications, such as beta-blockers, calcium channel blockers, diuretics, etc., for reducing the heart's workload and improving blood flow among patients is also creating a positive outlook for the market. Apart from this, the widespread adoption of transesophageal echocardiogram (TEE), which utilizes sound waves to create a superior quality image of the heart structures with greater depth and provide confirmed disease diagnosis, is further bolstering the market growth. Additionally, the escalating utilization of alcohol septal ablation, a non-surgical procedure, to treat the condition by injecting alcohol into one or more septal branches of the left anterior descending artery, is acting as another significant growth-inducing factor. Besides this, the rising usage of implantable cardioverter defibrillator therapy that can prevent sudden death in patients with an increased risk of ventricular arrhythmias, is expected to drive the hypertrophic cardiomyopathy market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the hypertrophic cardiomyopathy market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for hypertrophic cardiomyopathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hypertrophic cardiomyopathy market in any manner.

Recent Developments:

• In June 2023, Bristol-Myers Squibb announced that the European Commission (EC) had authorized CAMZYOS (mavacamten, 2.5 mg, 5 mg, 10 mg, and 15 mg capsules) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults. CAMZYOS is the first and only allosteric and reversible inhibitor of cardiac myosin that has been licensed in all European Union (EU) member states.
• In May 2023, Cytokinetics, Inc. announced that additional data from Cohort 4 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), a Phase 2 open-label clinical trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy, were presented in a Late Breaking Clinical Trial session at Heart Failure 2023, an International Congress of the European Society of Cardiology.

Key Highlights:

• Hypertrophic cardiomyopathy is the most common hereditary heart disease in the United States, accounting for one in every 500 cases.
• The frequency of hypertrophic cardiomyopathy in the general population worldwide is 0.2%, according to echocardiography studies.
• Echocardiography detects morphologic evidence of illness in roughly 25% of first-degree relatives of patients with hypertrophic cardiomyopathy.
• The disease is the most common cause of sudden cardiac death among people under the age of 30.
• Hypertrophic cardiomyopathy is slightly more common in males than in females.

Drugs:

CAMZYOS (mavacamten) is the first and only cardiac myosin inhibitor licensed in the United States. It is used to treat individuals with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy in order to enhance functional capacity and symptoms. CAMZYOS regulates the number of myosin heads that can enter the "on actin" (power-generating) state, lowering the likelihood of force-producing (systolic) and residual (diastolic) cross-bridge creation.

CK-3773274 (CK-274) is a unique oral small molecule cardiac myosin inhibitor intended to alleviate hypercontractility associated with hypertrophic cardiomyopathy. In preclinical models, CK-274 inhibits myocardial contractility by binding directly to cardiac myosin at a separate and specific allosteric binding site, preventing myosin from entering a force-producing state. CK-274 decreases the number of active actin-myosin cross bridges during each cardiac cycle, hence decreasing myocardial contractility.

IMB-1018972 (IMB-101) is an experimental cardiac mitotrope being developed for the treatment of cardiovascular diseases. It inhibits partial fatty acid oxidation (pFOX), thus increasing pyruvate dehydrogenase activity and glucose oxidation. IMB-101 is now undergoing three phase 2 proof-of-concept trials in individuals with hypertrophic cardiomyopathy.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the hypertrophic cardiomyopathy market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the hypertrophic cardiomyopathy market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current hypertrophic cardiomyopathy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance   
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the hypertrophic cardiomyopathy market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the hypertrophic cardiomyopathy market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the hypertrophic cardiomyopathy market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of hypertrophic cardiomyopathy across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of hypertrophic cardiomyopathy by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of hypertrophic cardiomyopathy by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with hypertrophic cardiomyopathy across the seven major markets?
• What is the size of the hypertrophic cardiomyopathy patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of hypertrophic cardiomyopathy?
• What will be the growth rate of patients across the seven major markets?
   

Hypertrophic Cardiomyopathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for hypertrophic cardiomyopathy drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hypertrophic cardiomyopathy market?
• What are the key regulatory events related to the hypertrophic cardiomyopathy market?
• What is the structure of clinical trial landscape by status related to the hypertrophic cardiomyopathy market?
• What is the structure of clinical trial landscape by phase related to the hypertrophic cardiomyopathy market?
• What is the structure of clinical trial landscape by route of administration related to the hypertrophic cardiomyopathy market?